BioRay Professional Service Team

We’re here to help! Please choose the service you need.：

Customer Service Hotline

Have questions about health supplements or daily skincare?

0800-200-026

Testing Inquiry

Want to learn more or book your personalized test?

06-505-2755

ODM/OEM

Looking for Health Supplement ODM/OEM Partnerships?

08-762-6868

Service Hours: Monday – Friday, 8:30 AM – 5:30 PM

History

Our Journey

Since its inception,BioRay has been guided by its core mission: "In Search of Harm-Free Medicine." Starting from deep-rooted R&D in Taiwan’s local probiotics, we have progressively expanded into high-end fields, including precision medical testing and cell therapy. Through continuous scientific innovation and international certifications, we transform the concept of preventive medicine into concrete clinical contributions.
From probiotics that safeguard gut health to precision immunotherapy targeting intractable diseases, G-Sheng Biotech is leveraging robust data and a global perspective to set new benchmarks in the international biotechnology industry.

Our Journey

CHAPTER 01

第一章

Building World-Class Infrastructure for Taiwanese Health

01

2020 | Excellence in Quality: Pingke Second Plant Achieves Multiple International Certifications, Fulfilling the Highest Commitment to Safe Production.

2020 | Excellence in Quality: Pingke Second Plant Achieves Multiple International Certifications, Fulfilling the Highest Commitment to Safe Production.

hree international food safety and quality certifications, constructing probiotic production lines to international specifications, ensuring every product meets the most stringent safety standards.
02

2021 | National Dual-Efficacy Recognition: Adjunctive Allergic Constitution Adjustment and Gastrointestinal Function Improvement—Dual Health Food Certification Renewed.

• October—Dual Health Food Certification No. A00201 for health claims [Adjunctive Adjustment of Allergic Constitution] and

[Gastrointestinal Function Improvement] extended to October 16, 2026

BioRay Biotech 's deep cultivation in functional probiotic R&D results in Product A00201 successfully passing Taiwan FDA review, simultaneously holding two health food certifications, with validity extended to 2026, continuing to safeguard national health.
03

2021 | Entering Precision Medicine: Tainan Branch GTP Laboratory Receives Taiwan FDA Recognition, Launching a New Era in Cell Therapy.

September—[Tainan Branch] Immune Cell Laboratory compliant with Good Tissue Practice (GTP) receives formal recognition from Taiwan FDA (Recognition No.: TP110C026)

This marks BioRay Biotech's capability to provide high-standard cell preparations, offering powerful technical support for cancer and immune therapy.
04

2021 | R&D Breakthrough: Patented High-Concentration "Cordyceps Xanthophyll" Successfully Developed, Positioning in Anti-Blue-Light Health Market.

October—BioRay Biotech successfully develops patented high-concentration Cordyceps xanthophyll with "anti-blue-light eye protection efficacy"

BioRay Biotech's R&D team breaks through key technologies, successfully developing patented high-concentration "Cordyceps xanthophyll." Proven to have excellent anti-blue-light eye protection efficacy, this not only enriches the group's patent portfolio but also provides more precise vision wellness solutions for the health market.
05

2021 | Precision Medicine Pinnacle: Cancer NGS Testing Achieves 100% Satisfactory Rating in Taiwan FDA Proficiency Testing.

December—BioRay Biotech Tainan Branch LDTS Laboratory participates in the "Proficiency Testing or Comparative Mechanism Analysis for Precision Medicine Molecular Testing Laboratories" program organized by Taiwan FDA, achieving 100% satisfactory results!

Through rigorous experimental protocols and professional analysis, BioRay Biotech achieves 100% satisfactory results in cancer NGS testing, with technical precision aligned to international standards.
06

2021 | Testing Capability Recognized: BioRay Biotech Tainan Branch Receives Satisfactory Rating in Mycoplasma Detection Proficiency Testing.

December—Congratulations! BioRay Biotech Tainan Branch Immune Function Testing Laboratory receives satisfactory certification for Mycoplasma detection

Through standardized testing protocols and sensitive analytical technologies, ensuring the accuracy and stability of testing data, deeply cultivating the fields of immune monitoring and pathogen detection.

CHAPTER 02

第二章

Transforming Cutting-Edge Technology into Accessible Warmth

01

2022 | Scientific Breakthrough: Successful Development of "Mulberry Leaf and Probiotic Symbiotic Fermentation" with Demonstrated Antiviral Potential.

May—New Discovery! BioRay Biotech's "Mulberry Leaf and Probiotic Symbiotic Fermentation" exhibits antiviral capabilities!

This R&D achievement not only expands the application scope of plant-microbe symbiosis but also lays a critical foundation for natural protective product development.
02

2022 | R&D Excellence Shines Internationally: Anti-Blue-Light Patented Technology Published in International Journals, Winning Gold Medal at Invention Exhibition.

May—BioRay Biotech's "Anti-Blue-Light R&D Results" Published in International Journals! Wins Gold Medal at International Invention Exhibition!

From laboratory data to international journal publication, to the tangible recognition of an invention exhibition gold medal, demonstrating the group's solid track record from R&D innovation to technology translation.
03

2022 | Clinical Treatment Breakthrough: Autologous CIK Immune Cell Therapy Program Receives Taiwan FDA Approval, Launching Cancer Cell Therapy Services.

July—Congratulations! BioRay Biotech's collaborative autologous CIK immune cell therapy program for solid tumors with Gaohe Hospital receives Taiwan FDA approval

With a professional cell preparation facility compliant with GTP standards, BioRay Biotech successfully passed Taiwan FDA review in July, partnering with medical institutions to implement CIK immune cell therapy programs. This approval validates BioRay's high level of expertise in cell preparation quality and safety, strengthening precision medicine capabilities.

CHAPTER 03

第三章

Sharing Taiwan's Warmth with Asia and the World

01

2024 | Expanding into International Markets: Licensing to Indonesia's BGI to Launch Southeast Asia Strategy, Exporting Top-Tier Biotechnology.

January—BioRay Biotech licenses to Indonesia's BGI, launching Southeast Asia biotech strategic layout

Through core technology export and resource integration, BioRay brings Taiwan's premium probiotic R&D and precision medicine capabilities to the international stage, opening a new chapter in global operations.
02

2024 | R&D Excellence Shines Internationally:

BioRay Biotech Wins International Invention Exhibition Gold Medal for Developing High-Value Health Ingredients from Lemon By-Products and Lactobacillus plantarum Symbiotic Fermentation for Sarcopenia Prevention!

 

May—BioRay Biotech successfully develops patented fermentation technology, transforming lemon by-products into high-value raw materials for sarcopenia prevention. This innovation not only implements circular economy principles but also wins international invention exhibition gold medal recognition through exceptional technical capabilities.

BioRay Biotech has long invested in probiotic and symbiotic fermentation technology R&D, ensuring product safety and efficacy through unique platform technologies, advanced scientific validation, and human clinical evidence, earning widespread trust from domestic and international clients.
03

2025 | Expanding Global Business Footprint: BioRay Biotech Officially Signs with Jiayan International to Expand Overseas Markets, Building Momentum for Next Year's IPO!

May—BioRay Biotech announces the formal signing of a partnership agreement with Jiayan International, an expert in international raw material supply and product incubation, to jointly expand the overseas (excluding Taiwan) health supplement market. This strategic alliance will inject strong growth momentum into BioRay Biotech's IPO plan for next year, significantly expanding its international market presence and revenue.

BioRay Biotech and Jiayan International have reached a strategic partnership, accelerating international channel deployment through combined strengths. This move not only strengthens overseas market influence but also lays a solid foundation for next year's IPO goal, marking a new milestone toward capital markets.

This Track Record Is Our Promise to You

From 2020 to the future, every step BioRay takes is imprinted with the original intention of "technology as the backbone, care as the soul."
As we approach the new milestone of an IPO, we want you to know: No matter how far we go, we will always be that health partner dedicated to "seeking medicine without harm"—worthy of your trust.